-continued

```
Arg Arg Pro Ile Arg Asn Leu Thr Phe Gln Asp Leu
1               5                   10


<210> SEQ ID NO 273
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VSTB112 minor epitope 1

<400> SEQUENCE: 273

Thr Trp Tyr Arg Ser Ser Arg Gly Glu Val Gln Thr Cys Ser
1               5                   10


<210> SEQ ID NO 274
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VSTB112 minor epitope 2

<400> SEQUENCE: 274

Glu Ile Arg His His His Ser Glu His Arg Val His Gly Ala Met Glu
1               5                   10                  15

Leu


<210> SEQ ID NO 275
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: IGN175A epitope

<400> SEQUENCE: 275

Phe Lys Val Ala Thr Pro Tyr Ser Leu Tyr Val Cys Pro Glu Gly Gln
1               5                   10                  15

Asn Val Thr Leu Thr Cys Arg Leu Leu Gly Pro Val Asp Lys Gly His
            20                  25                  30
```

1.-**53**. (canceled)

54. An antigen-binding molecule which binds to VISTA and inhibits VISTA-mediated signalling, comprising:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:33

HC-CDR2 having the amino acid sequence of SEQ ID NO:34

HC-CDR3 having the amino acid sequence of SEQ ID NO:35;

or a variant thereof, in which one amino acid of HC-CDR1, two amino acids of HC-CDR2 and one amino acid of HC-CDR3 are substituted with another amino acid; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:42

LC-CDR3 having the amino acid sequence of SEQ ID NO:43;

or a variant thereof, in which one amino acid of LC-CDR2 is substituted with another amino acid.

55. The antigen-binding molecule according to claim **54**, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:32; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:40.

56. The antigen-binding molecule according to claim **54**, wherein the antigen-binding molecule is capable of inhibiting interaction between VISTA and a binding partner for VISTA.

57. The antigen-binding molecule according to claim **54**, wherein the antigen-binding molecule is capable of increasing proliferation and/or cytokine production by effector immune cells.

58. A method of treating or preventing a cancer in a subject, the method comprising administering to a subject a therapeutically or prophylactically effective amount of an